Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)

PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

September 30, 2018

Study Completion Date

October 31, 2018

Conditions
Condyloma AcuminataGenital WartsCondylomata AcuminataVenereal Warts
Interventions
DRUG

Vehicle gel

"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."

DRUG

SR-T100 gel with 1.0 % SM

"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."

DRUG

SR-T100 gel with 2.3% SM

"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."

Trial Locations (3)

Unknown

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung City

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
lead

G&E Herbal Biotechnology Co., LTD

INDUSTRY

NCT01796821 - Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs) | Biotech Hunter | Biotech Hunter